Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GHTF docs

This article was originally published in The Gray Sheet

Executive Summary

FDA is requesting 1comments by April 25 on Global Harmonization Task Force study group documents released in 2005, including the proposed guidances, "Principles of Medical Devices Classification," "Guidelines for Regulatory Auditing of Quality Management Systems - Part 2: Regulatory Auditing Strategy" (2"The Gray Sheet" Dec. 5, 2005, p. 18). The agency is also requesting feedback on the final documents, "Information Document Concerning the Definition of the Term 'Medical Device'" and "Essential Principles of Safety & Performance of Medical Devices" (3"The Gray Sheet" Aug. 1, 2005, p. 17)...

You may also be interested in...

GHTF Adverse Event Reporting Guidance Is A Stride Toward Harmonization

Adverse device side effects can go unreported as long as they are clearly identified in the manufacturer's labeling, according to a Nov. 17-posted Global Harmonization Task Force guidance document

GHTF To Draft New IVD Guidelines Following Expansion Of Device Definition

The Global Harmonization Task Force endorses the inclusion of in vitro diagnostics in further device-related harmonization efforts in a final document defining "medical device" released July 21

Amunix Raises $117m To Take Novel T-Cell Engager Into The Clinic

Amunix’s XTEN technology for half-life extension and precise drug delivery has been used by multiple partners over the past 15 years, but now the firm is building its own cancer therapy pipeline.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts